Compare ADMA Biologics Inc (ADMA) vs Booz Allen Hamilton Holding Corporation (BAH) Price & Performance
Price performance
Price movement over the last 24 hours
Key statistics
Key statistics
ADMA Biologics Inc vs Booz Allen Hamilton Holding Corporation — how do they compare? ADMA Biologics Inc trades at $9.18 (market cap $2.13B), while Booz Allen Hamilton Holding Corporation trades at $63.44 (market cap $7.59B). The key difference: Booz Allen Hamilton Holding Corporation is far larger — about 3.6× ADMA Biologics Inc's market cap, and Booz Allen Hamilton Holding Corporation pays a 3.73% dividend while ADMA Biologics Inc pays none. Which is the better fit depends on your goals.
| ADMA | BAH | |
|---|---|---|
Market Cap | $2.13B | $7.59B |
Sector | Health | Industrials |
52-Week High | $20.38 | $115.95 |
52-Week Low | $7.60 | $59.71 |
Enterprise Value | $2.20B | $10.99B |
Dividend Yield | — | 3.73% |
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
ADMA trades at $9.16, up 2.35% today, with a bullish technical signal from moving averages and oscillators. The company reported strong profitability with a 32.43% net income margin and 43.3% ROE for 2025, though recent EPS results were mixed. Analyst consensus is strongly bullish with an $19.00 price target, but multiple class action lawsuits filed in July 2026 alleging securities fraud create significant near-term uncertainty.
The stock offers substantial upside to analyst targets if legal challenges are resolved favorably, supported by robust fundamentals and projected cash flow growth. Primary risks include the outcome of ongoing litigation and potential reputational damage. Investors should weigh strong financial performance against elevated legal and sentiment risks before establishing a position.
Booz Allen Hamilton (BAH) trades at $63.31, up 1.38% with mixed technical signals showing bearish moving averages but neutral oscillators. The company demonstrates strong fundamentals with revenue growth to $12.0B in 2025 and impressive profitability metrics including 80.17% ROE. Recent developments include strategic AI partnerships with OpenAI and acquisitions to strengthen defense technology capabilities, though the stock faces near-term pressure from civil business weakness.
BAH presents a compelling value opportunity with attractive valuation multiples (P/E 9.03, P/S 0.68) and analyst consensus target of $87.25 representing 38% upside. However, investors face risks from FY27 transition expectations, civil segment pressures, and technical resistance near $64-65 levels. The company's government-focused model provides stability amid market volatility.
Returns comparison
Trailing returns across standard periods
Returns comparison
Trailing returns across standard periods
Top news
Latest headlines on both assets
Top news
Latest headlines on both assets
About ADMA Biologics Inc
ADMA Biologics is a biopharmaceutical company specializing in plasma-derived therapies for immunodeficient patients. Key products like ASCENIV and BIVIGAM treat primary humoral immunodeficiency and help prevent infectious diseases.
Read more on ADMA →About Booz Allen Hamilton Holding Corporation
Booz Allen Hamilton Holding Corp is a provider of management consulting services to the U.S. government. Other services offered include technology, such as cloud computing and cybersecurity consulting, and engineering consulting. The consulting services are focused on defense, intelligence, and civil markets. In addition to the U.S. government, Booz Allen Hamilton provides its management and technology consulting services to large corporations, institutions, and nonprofit organizations. The company assists clients in long-term engagements around the globe.
Read more on BAH →
